ADMA: Ascending Triangle detected on 25 Jun 2026

ADMA is forming an ascending triangle pattern as the stock consolidates near resistance at $8.85, with the pattern demonstrating solid structure (15.0/15) and breakout confirmation potential (12.5/13). Current price of $8.7 sits 20.67% above its 52-week low and 57.48% below its 52-week high, reflecting recovery from recent volatility. Volume is tracking slightly below average at 0.89x (3.19M vs. 3.57M 20-day average), which is the pattern's only minor weakness. The ascending triangle structure—higher lows and resistance holding steady—suggests institutional accumulation. An RSI of 53.46 indicates neutral momentum, neither overbought nor oversold, while MACD histogram at 0.129 shows positive but modest momentum building.

ADMA reported Q1 2026 results on May 6, 2026, with flat year-over-year total revenue of $114.5M but ASCENIV revenue growing 28% YoY. Management noted increased competitive dynamics in the plasma-derived therapies and immunoglobulin market impacted BIVIGAM, though ASCENIV fundamentals remained strong with record utilization growth. On May 4, 2026, the FDA approved label expansion for ASCENIV to include pediatric immune compromised patients ages 2 and older, a meaningful market expansion catalyst. Full-year 2025 delivered $510.2M revenue (+20% YoY) and $363M ASCENIV sales (+51% YoY), with ~$88M cash on hand and FY2026–2029 guidance targeting >$1.1B revenue and >$700M adjusted EBITDA by 2029. However, in March 2026, short-seller allegations of channel stuffing emerged, triggering a 16.6% drop on March 24 and a Cantor downgrade on March 26, with ongoing class action litigation filed as recently as June 24, 2026. The pattern is forming amid genuine product strength (ASCENIV growth) but lingering litigation risk.

The ascending triangle breakout above $8.85 resistance would target $9.05 (target_conservative), representing a 3.9% move—modest but aligned with the pattern's measured objective. Historical win probability of 60.95% suggests better-than-coin-flip odds for upside breakout. Volume confirmation will be critical: the pattern needs volume expansion above the 0.89x current ratio to validate breakout conviction. Invalidation occurs at key_support of $8.41 (down 3.3% from current), which would negate the ascending structure and signal failed consolidation. 2026 is positioned as ADMA's first full year of yield-enhanced production in routine commercial execution, a margin accretion catalyst that supports the upside narrative if breakout confirms.

The stock fell $3.96 (29.1%) over March 24–25, 2026, after short-seller allegations of channel stuffing related to the reported 20% FY2025 growth, with ongoing class action litigation (lead plaintiff deadline August 10, 2026) creating legal overhang and reputational pressure. Q1 2026 revealed increased competitive dynamics in plasma-derived therapies and immunoglobulin markets, with variability in distributor ordering patterns creating near-term topline pressure. Litigation tail risk is material—discovery and settlement uncertainty could distract management and pressure valuation multiples through late 2026–2027. Beta of 0.36 is defensive, but volatility at 34.73% is elevated for a healthcare biotech, reflecting stock-specific litigation risk. The 3-month loss of 23.21% shows the damage recent litigation caused; while the stock has recovered 5.58% in the past month and 7.14% in 2 weeks, the litigation noise persists and could re-ignite on unfavorable legal developments. Monitor next earnings (likely Q2 in August) for any revenue guidance cuts driven by competitive market dynamics or distributor de-stocking.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.